Core Viewpoint - Enlivex Ltd. has successfully completed a $21 million debt financing agreement, which will support its operational plans and acquisition of RAIN tokens, while also implementing a share repurchase program to enhance shareholder value [1][2][3][6]. Group 1: Debt Financing - Enlivex secured a $21 million debt financing agreement with The Lind Partners, resulting in net proceeds of approximately $18.7 million after offering expenses [1][4]. - The note from the financing is convertible into Enlivex's ordinary shares at a fixed price of $2.69175 per share, representing a 264% premium to the Nasdaq closing price on March 20, 2026 [1][6]. Group 2: Acquisition of RAIN Tokens - The company exercised an option to acquire 3,030,303,030 RAIN tokens at a price of $0.0033 per token, which is a 62% discount to its closing price on March 22, 2026, totaling an aggregate purchase amount of $10 million [2][6]. - The duration of the option to acquire an additional 272,121,212,121 RAIN tokens at the same price has been extended from November 30, 2026, to December 31, 2027 [2][6]. Group 3: Share Repurchase Program - The Board of Directors approved a share repurchase program allowing the company to buy back up to $20 million of its outstanding ordinary shares, subject to regulatory requirements [2][6]. - The repurchase may occur through various means, including open market transactions and privately negotiated transactions, with no obligation to purchase any shares [2][6]. Group 4: Company Overview - Enlivex is a quality longevity company focused on advancing Allocetra™, an advanced clinical-stage immunotherapy targeting age-related inflammatory conditions, particularly osteoarthritis [5][7]. - The company operates a prediction markets treasury strategy based on the RAIN protocol, integrating the development of therapeutics with exposure to the prediction markets ecosystem [7].

Core Insights - 2025 was a transformational year for Cypherpunk Technologies, marked by a $58.88 million private placement and a rebranding to focus on privacy technology and digital asset treasury strategy centered on Zcash [2][4]. Financial Highlights - The company reported a net income of $4.8 million for the year ended December 31, 2025, a significant turnaround from a net loss of $67.8 million in 2024, primarily due to $50.4 million in unrealized gains on ZEC treasury holdings [8][20]. - Research and development expenses decreased to $25.7 million in 2025 from $57.2 million in 2024, attributed to reduced clinical trial and manufacturing costs [9]. - General and administrative expenses were $10.9 million in 2025, down from $12.8 million in 2024, mainly due to decreased payroll and related expenses [10]. - Cash and cash equivalents totaled $14.0 million as of December 31, 2025, with ZEC treasury holdings valued at $147.4 million [11][21]. Strategic Developments - The company acquired 294,743.10 ZEC for its treasury and made a $5 million strategic investment in Zcash Open Development Lab (ZODL), enhancing its position in the Zcash ecosystem [3][5]. - Key appointments included industry leaders as board members and strategic advisors, such as Arjun Khemani and Zooko Wilcox, to strengthen the company's expertise in the digital asset space [6]. Subsidiary Progress - Leap Therapeutics, a subsidiary, presented final clinical data from the DeFianCe study for sirexatamab in colorectal cancer patients, indicating promising results in specific patient groups [7][13]. - The company is working on advancing a DKK1 biomarker diagnostic test and engaging with regulatory authorities for the registrational pathway of sirexatamab [7].

Core Insights - Peter Thiel's Founders Fund has completely divested from ETHZilla, a digital asset treasury firm holding Ethereum, amid a downturn in the crypto market [1][4] - The digital asset treasury strategy gained traction last year, with firms accumulating cryptocurrencies as reserve assets, but the current market conditions have led to significant pressure on these firms [2][4] Company Performance - ETHZilla, formerly known as 180 Life Sciences, has faced challenges due to the declining value of Ethereum, reducing its holdings from over 100,000 ETH to 69,802 ETH [8][9] - The company has executed multiple sales of Ether, including a $40 million sale for share buybacks and a subsequent $74.5 million sale to repay debt [8][9] Market Context - Ethereum experienced a 28.4% decline in Q4 2025, marking its first negative fourth quarter since 2022, with further declines in early 2026 [5] - The broader crypto market has been under pressure, with significant losses reported by digital asset treasury firms, including BitMine, which has unrealized losses exceeding $7 billion [7]

Core Viewpoint - The listing of the RAIN token on the Kraken cryptocurrency exchange is expected to enhance liquidity and accessibility for participants in the RAIN ecosystem, contributing to improved price discovery and secondary market trading [1][3]. Group 1: Company Overview - Enlivex Therapeutics Ltd. is focused on the late-stage clinical development of Allocetra™, a novel therapy for osteoarthritis, and has adopted a treasury strategy centered on the RAIN token [4]. - RAIN serves as the governance and utility token for a decentralized predictions and options protocol built on the Arbitrum network, allowing users to create and trade markets tied to real-world events [3]. Group 2: Market Context - Kraken, the second-largest U.S.-based cryptocurrency exchange, supports a wide range of digital assets and had a total trading volume exceeding $2 trillion in 2025, making it a significant platform for secondary market trading [2]. - The exchange is known for its strong security, regulatory compliance, and transparency, attracting institutional and professional market participants [2]. Group 3: Clinical Development Focus - Osteoarthritis affects over 32.5 million Americans and more than 300 million individuals globally, with projections indicating that 78 million Americans will have the condition by 2040 [5]. - The burden of osteoarthritis is substantial, leading to over one million hospitalizations annually in the U.S., primarily for total joint replacement, highlighting the critical need for effective treatments [5].

Core Viewpoint - Zacks Investment Research has initiated coverage of iPower Inc. (IPW) with a "Neutral" recommendation, reflecting a mixed outlook for the company amid its progress in the e-commerce sector despite industry challenges [1] Company Overview - iPower operates as a technology- and data-driven online retailer based in Rancho Cucamonga, CA, offering a variety of consumer goods including home goods, pet products, gardening and hydroponics equipment, outdoor products, and consumer electronics, along with e-commerce services for third-party brands [2] Financial Performance - iPower's first-quarter fiscal 2026 revenue decreased by 36.8% year over year, primarily due to reduced order volumes from Amazon and supply chain disruptions [3] - Service revenue has more than doubled compared to the previous year as iPower expanded its supply-chain and logistics platform, indicating a shift in revenue mix [3] Growth Drivers - A significant reset of the cost structure has improved operating leverage, leading to reduced losses despite revenue pressures [4] - Balance-sheet improvements, including debt repayment and enhanced financing capacity, have lowered near-term risks and provided flexibility for strategic initiatives [4] - Domestic sourcing efforts and a disciplined digital asset treasury strategy are aimed at enhancing supply-chain resilience and capital deployment [4] Market Positioning - iPower's stock has underperformed compared to industry peers and the broader market over the past year, indicating investor caution regarding the company's near-term recovery and execution [6] - The current valuation suggests that expectations are low, which could lead to a sharp response in stock price with sustained operational or financial improvements [6]

Core Viewpoint - Enlivex Therapeutics has successfully listed its primary treasury asset, the RAIN token, on the WhiteBIT cryptocurrency exchange, enhancing market access and liquidity for the token [1][2]. Group 1: Company Overview - Enlivex Therapeutics is a clinical stage company focused on macrophage reprogramming immunotherapy, particularly in the late-stage clinical development of Allocetra™, aimed at treating osteoarthritis [4]. - The company has developed a treasury strategy centered on RAIN, which serves as its primary treasury reserve asset, providing investors with exposure to digital capital [4]. Group 2: RAIN Token and Market Strategy - The RAIN token is the governance and utility token of a decentralized predictions and options protocol on the Arbitrum network, allowing users to create and trade markets tied to real-world events [3]. - The listing of RAIN on WhiteBIT, the largest European cryptocurrency exchange by traffic, is expected to broaden regional market access and enhance secondary market liquidity, supporting the development of market infrastructure for Enlivex's digital asset strategy [2]. Group 3: Osteoarthritis Market Context - Osteoarthritis affects over 32.5 million Americans and more than 300 million individuals globally, with projections indicating that 78 million Americans will have the condition by 2040 [5]. - The burden of osteoarthritis is significant, leading to over one million hospitalizations annually in the U.S., primarily for total joint replacement, highlighting the critical need for effective treatments [5].

Core Viewpoint - Enlivex Therapeutics Ltd. has announced its decision to voluntarily delist its ordinary shares from the Tel Aviv Stock Exchange (TASE) to focus on U.S.-based trading and reduce administrative costs associated with dual listing [1][4]. Group 1: Delisting Process - The last trading day for the ordinary shares on the TASE is expected to be April 23, 2026, with delisting anticipated around April 26, 2026 [2]. - Shareholders will continue to trade ordinary shares on the TASE until the final trading day [2]. - The ordinary shares will continue to be traded on the Nasdaq Capital Market under the symbol "ENLV" [3]. Group 2: Strategic Objectives - The Board of Directors approved the delisting to operate under a single set of listing requirements, which aims to reduce duplicative administrative costs and potentially enhance liquidity on Nasdaq [4]. - The transition allows the company to concentrate its investor and public relations efforts on the U.S. capital markets [4]. Group 3: Company Overview - Enlivex is a clinical-stage biotech company focused on macrophage reprogramming immunotherapy, particularly in the late-stage clinical development of Allocetra™, a therapy for osteoarthritis [5]. - Osteoarthritis affects over 32.5 million Americans and is projected to impact 78 million by 2040, highlighting a significant market need for effective treatments [6].

Core Insights - Sharps Technology, Inc. has entered into a 90-day lock-up agreement with SOL Markets, indicating strong confidence in its execution roadmap and alignment between the parties [1][2][3] - The company has also announced a share buyback program for up to $100 million, reflecting its commitment to enhancing shareholder value [1] Group 1: Lock-Up Agreement - The lock-up agreement restricts SOL Markets from selling, transferring, or disposing of any warrants or underlying shares of STSS common stock for 90 days, effective January 16, 2026 [2] - This commitment reinforces SOL Markets' alignment with STSS's objectives and demonstrates confidence in the anticipated growth of their combined initiatives [2][3] Group 2: Management and Strategic Partnerships - STSS's management is actively engaging with institutional investors through non-deal roadshows to showcase upcoming initiatives [4] - The company is developing a universal framework for digital identity and authentication through strategic partnerships with Coinbase, Crypto.com, and Jupiter, alongside its Solana treasury and product R&D initiatives [3]

Core Viewpoint - Enlivex Therapeutics has successfully listed its primary digital treasury asset, the RAIN token, on the KuCoin cryptocurrency exchange, enhancing market access and liquidity for the token [1][2]. Group 1: Company Overview - Enlivex Therapeutics is the first publicly-listed company to develop a treasury strategy centered on the RAIN token, which serves as its primary treasury reserve asset [4]. - The company is also engaged in the late-stage clinical development of Allocetra™, a novel therapy for osteoarthritis, a condition affecting over 32.5 million Americans and more than 300 million people globally [5]. Group 2: RAIN Token and Digital Asset Strategy - The RAIN token is the governance and utility token of a decentralized predictions and options protocol built on the Arbitrum network, allowing users to create and trade markets tied to real-world events [3]. - The listing of RAIN on KuCoin is expected to significantly enhance global market access and secondary liquidity for Enlivex's digital asset treasury [2][3]. Group 3: KuCoin Exchange - KuCoin is a leading global cryptocurrency exchange with over 40 million users, primarily in Southeast Asia, and ranks among the top ten cryptocurrency exchanges worldwide [2]. - The exchange offers a comprehensive suite of trading products, including spot trading, derivatives, and yield services, which will benefit the trading of RAIN [2].

Core Viewpoint - Pineapple Financial Inc. has appointed Anthony Georgiades to its Board of Directors and the newly formed Special Advisory Committee to oversee its digital asset treasury strategy focused on accumulating Injective ($INJ) tokens [1][2]. Group 1: Appointment and Role - Anthony Georgiades, General Partner at Innovating Capital, will guide governance, risk management, and strategic execution of Pineapple's digital asset treasury [2][3]. - His experience in digital assets, institutional investing, and technology infrastructure is seen as a valuable addition to the Board and Special Advisory Committee [3]. Group 2: Company Strategy - Pineapple aims to modernize financial services through AI, data, and blockchain technology, integrating on-chain infrastructure into its operating and capital framework [2][3]. - The company is combining a modern mortgage technology platform with an Injective-based digital asset treasury to bring real-world mortgage data on-chain [3]. Group 3: Company Background - Pineapple Financial Inc. is a leading Canadian fintech and mortgage brokerage network, focusing on the success of agents and brokers as well as enhancing the homeowner experience [4]. - The company develops cloud-based tools and AI-driven systems to assist brokers in helping Canadians achieve homeownership [4].